Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277272 | 0.93 | TSHR (0.48) | TSHRALOX15SMN1; SMN2ADH1BADH1C | |
| SCHEMBL28009314 | 0.91 | ADH1B (0.48) | TSHRALOX15ADH1BADH1CADH1A | |
| SCHEMBL276686 | 0.91 | ADH1B (0.48) | TSHRALOX15ADH1BADH1CADH1A | |
| SCHEMBL314509 | 0.91 | ADH1B (0.48) | TSHRALOX15ADH1BADH1CADH1A | |
| SCHEMBL277071 | 0.85 | TSHR (0.54) | TSHRALOX15SMN1; SMN2ADH1BADH1C | |
| SCHEMBL270377 | 0.79 | TSHR (0.41) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL271285 | 0.77 | TSHR (0.40) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL269989 | 0.74 | TSHR (0.46) | TSHRALOX15ALDH1A1 | |
| SCHEMBL728057 | 0.73 | ADH1B (0.44) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL8733682 | 0.71 | TSHR (0.39) | TSHRSMN1; SMN2ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3858909-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112839988-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2021-05-25 | — | — | CN | disclosed |
| WO-2020067144-A1 | NUCLEATING AGNET, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | 株式会社ADEKA | 2020-04-02 | — | — | WO | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-1698620-B1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | EISAI R&D MAN CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-0934296-B1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6555574-B1 | Antiarrhythmic agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| WO-2003000675-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AGAINST ARRHYTHMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-03 | — | — | WO | disclosed |
| US-6486178-B1 | Indane derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| WO-2002064581-A1 | 4-AMINOBENZOPYRAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-22 | — | — | WO | disclosed |
| EP-1085009-A1 | INDAN DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | NOC2L, RIF1, NAP1L1 | TSHR 3052/4885ALOX15 1998/4885SMN1; SMN2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.